Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
23.97 CNY +1.48% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +2.52% -4.23%
Jun. 07 Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3% MT
Jun. 03 Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7% MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Stock Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-4.23% 8.01B
A
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.39% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.13% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.61% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.00% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.11% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.80% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.50% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.